Sm_mary In this study we have investigated the role of thrombospondin (TSP) as a possible ligand playing a key role in human M3Da. melanoma cell interaction with platelets and in tumour growth. TSP is secreted (80 ± 6 ng TSP 1O-' cells) Keyword: thrombospondin; melanoma; monoclonal antibodies; platelet aggregation; vitronectin receptor Thrombospondin (TSP) is a high molecular weight (450 kDa) glycoprotein (GP) that is released from the a-granules of platelets during activation (Lawler, 1986) . In the presence of a physiological concentration of calcium, TSP binds to the surface of stimulated platelets and plays an active role in promoting platelet aggregation (Leung, 1984; Boukerche and McGregor, 1988; McGregor and Boukerche, 1993 al., 1986, 1989). In addition to its role in blood coagulation, TSP has been reported to promote adhesion and motility of several of these cell types (Walz, 1992) . Released TSP will bind to the surface of activated platelets or cells via a number of glycoprotein receptors, such as the integrins GPIIb-IIIa (oEA,) and m2p, Tuszynski and Kowalska, 1991) , the vitronectin receptor a, (Lawler et al., 1988) , GPIV (also called CD36) (Asch et al., 1987; McGregor et al., 1989) , the integrin-like receptor (105/80 kDa) (Yabkowitz and Dixit, 1991) and the heparan sulphate proteoglycans (Roberts, 1988) . Recently, it was shown that tumour formation and the metastatic spread of lung tumours in mice was increased by TSP and was significantly reduced by use of TSP peptide CSVTCG or a TSP cDNA antisense expression vector (Tuszynski et al., 1987 (Tuszynski et al., , 1992 Castle et al., 1991 However, so far very little is known about the precise biological role of TSP in tumour-platelet interactions and tumour cell growth. Moreover, the identity of the TSP receptor(s) mediating tumour cell-platelet interactions and tumour growth remains to be elucidated. We have previously reported that a monoclonal antibody (LYP18), generated against human blood platelet glycoprotein lIb-Illa (muA), immunoprecipitated two proteins from a tumorigenic human melanoma cell line (M3Da.) immunologically related to the vitronectin receptor (a,3) (Boukerche et al., 1989a,b 
Sm_mary In this study we have investigated the role of thrombospondin (TSP) as a possible ligand playing a key role in human M3Da. melanoma cell interaction with platelets and in tumour growth. TSP is secreted (80 ± 6 ng TSP 1O-' cells) and bound to the surface of M3Da. cells via receptors different from CD36, as shown by biosynthetic labelling and immunofluorescence studies. The levels of TSP binding to M3Da. cells evaluated by binding studies, using an anti-TSP monoclonal antibody (MAb) (LYP8), shows 367 000 ±58 000 (mean ± s.d.) LYP8 binding sites per cell with a dissociation constant (Kd) of 67 nrM. TSP binding to M3Da. cells shows 400 000 ± 50 000 TSP binding sites per cell with a Kd of l0 nM. The capacity of anti-TSP MAb (LYP8) to inhibit M3Da.-platelet interactions was followed on an aggregometer and evaluated by electron microscopy studies. The biological role of TSP binding to M3Da. cells was investigated by implanting subcutaneously the M3Da. cel line in nude mice and following the size and time of in vivo tumour growth. Reducing the availability or the functional level of TSP by using an anti-TSP MAb (LYP8) resulted in a significant decrease Keyword: thrombospondin; melanoma; monoclonal antibodies; platelet aggregation; vitronectin receptor Thrombospondin (TSP) is a high molecular weight (450 kDa) glycoprotein (GP) that is released from the a-granules of platelets during activation (Lawler, 1986) . In the presence of a physiological concentration of calcium, TSP binds to the surface of stimulated platelets and plays an active role in promoting platelet aggregation (Leung, 1984; Boukerche and McGregor, 1988; McGregor and Boukerche, 1993) . TSP is also secreted by a variety of cells, such as pneumocytes, endothelial cells, macrophages, fibroblasts, smooth muscle cells, chondrocytes and mesangial cells, as well as by a number of tumour cell lines, including melanomas and carcinomas (Varani et al., 1986 (Varani et al., , 1989 . In addition to its role in blood coagulation, TSP has been reported to promote adhesion and motility of several of these cell types (Walz, 1992) . Released TSP will bind to the surface of activated platelets or cells via a number of glycoprotein receptors, such as the integrins GPIIb-IIIa (oEA,) and m2p, Tuszynski and Kowalska, 1991) , the vitronectin receptor a, (Lawler et al., 1988) , GPIV (also called CD36) (Asch et al., 1987; McGregor et al., 1989) , the integrin-like receptor (105/80 kDa) (Yabkowitz and Dixit, 1991) and the heparan sulphate proteoglycans (Roberts, 1988) . Recently, it was shown that tumour formation and the metastatic spread of lung tumours in mice was increased by TSP and was significantly reduced by use of TSP peptide CSVTCG or a TSP cDNA antisense expression vector (Tuszynski et al., TSP plays a major role in cell adhesion and cell-cell interactions in the metastatic process.
However, so far very little is known about the precise biological role of TSP in tumour-platelet interactions and tumour cell growth. Moreover, the identity of the TSP receptor(s) mediating tumour cell-platelet interactions and tumour growth remains to be elucidated. We have previously reported that a monoclonal antibody (LYP18), generated against human blood platelet glycoprotein lIb-Illa (muA), immunoprecipitated two proteins from a tumorigenic human melanoma cell line (M3Da.) immunologically related to the vitronectin receptor (a,3) (Boukerche et al., 1989a,b (Boukerche et al., 1989a (PRP) . Aggregation studies were performed with platelets in PRP adjusted to 3 x 10' cells ml-' and melanoma cells preincubated for 1 h at 3TC before addition to 0.4 ml of PRP (Boukerche et al., 1989a (Boukerche et al., 1989a) .
Electron microscopy ofplatelet-melanoma interaction At the end of the aggregation curve, platelet-mnlanoma suspensions were fixed with 0.15% glutardehyde in 0.1 mol I' cacodylate buffer and then filtered through 0.22 pm filters (Millpore, France). The fixed material was processed for electron microscopy as previously described using a Siemens ELM 102 transmission electron microscope (Boukerche et al., 1989a) .
Immunoprecipitation
Confluent melanoma cells were metabolcaBlly labelled with I'S for 24h and chased for 18 h in the absence of labelled methionine. The Triton X-100-extracted melana chase media were immunoprecipitated with an anti-TSP MAb (LYP8) or a non-immune mouse serum IgG and analysed by sodium dodecyl sulphate-polyacrylamide gel eectrophoresis (SDS-PAGE) as previously described (Boukerche et al., 1989b) .
Isolation of thrombospondn and vitronectin receptors Thrombospondin (TSP) was purified from the superatant of ionophore-actiated human platelets on a heparin-Sepharose CL-6B column in the presence of 2 mm calcium following the method of Lawler et al., (1988) . Vitronectin receptor (VnR) was isolated from melanoma cells by LYP18-affinity chromatography as previously described (Boukerche and McGregor, 1988) . The VnR was more than 95% pure when analysed by SDS-PAGE.
Bindng studies
Human melanoma cells grown to confluence in serum-free RPMI were detached from culture plates by brief treatment with trypin-EDTA and ressended in RPMI-1640 containing 0.35% BSA_ Thrombospondin (TSP) or isolated antibody was labelled with 'lI as previously described (Boukerche and McGregor, 1988) . Labelled TSP or antibody was separated from free '2I on a PD-10 column (Sephadex G-25 M). Increasing concentrations of '25I-labelled TSP (0.4-24 pg ml-') or '25I-labelled LYP8 (0.4-24 pg ml-) were added to 10' cells and incubated overnight at 4C. At the end of the incubation time, aliquots of the melanoma-antibody or melanoma-TSP mixture were layered in tripliate in 400 p1 Eppendorf tubes contining 20% sucrose, 2% bovine serun albumin prepared in PBS, pH 7.2. The amount for 'WI-labelled TSP or "5I-labelled LYP8 bound per melanoma cell was determined by counting the radioactivity of the cut-off centrifuge tips. Non-specific binding was measured by incubating cells with a 100-fold excess of unlabeled TSP or monoclonal antibody. This non-specific binding (less than 10-15%) was subtracted from the total binding. The number of binding sites per cell and the dissociation constant were obtained by double-reciprocal plots and least-squares regression analyis. The valus reported are the mean of three expeiments. Binding of TSP to vitronectin receptor was studied using an ELISA as described previously (Boukerche and McGregor, 1988) . Briefly, purified 3 (2-3 pg) diluted in PBS, pH 7.2, contaig 2 mM calcium chloride was adsorbed on each well of the microtitre plate for overnight incubation at 4C. Wells were then washed in PBS containing 1 mM calcium chloride supplemented with 0.05% Tween 20, and inraeasing concentrations of TSP or albumin (0.1-1.5 pg) diluted in PBS containing 2 mM calcium chloride were added to wells for ovemight incubation at 4C. Plastic wells were then washed and anti-TSP polyclonal antibody was added for I h at 37C to detect bound TSP. After additional washes, goat anti-rabbit antibody conjugated to horseradish peroxidase was added and bound anti-TSP polyclonal antibody was quantified by the addition of the substrate orthophenydiethylanine. (1 x 10') were grafted subcutaneously (s.c.), as previously described (Boukerche et al., 1989b) , on the ventral surface of nude mice, after preincubation for 20 min with purified LYP8 (24pg 10'-), LYP18 (7 pg 10-'), a non-immune mouse (Figure lb) (Boukerche et al., 1989b (Asch et al., 1987; McGregor et al., 1989; Silverstein et al., 1992) . These results clearly demonstrate that M3Da_ synthebse and secrete into the culture medium a protein immunologically related to TSP that binds to the cell surface via receptors different from CD36. (Figure 3 ). Anti-TSP MAbs, LYPIO or LYP12, used at the same concentration or a non-immune mouse serum IgG, had no effect on platelet aggregation induced by melanoma cells. As previously shown, an anticac MAb (LYP18) added to M3Da. cells sign tly inhibited platelet aggregation induced by M3Da_ cells ( Figure  3 ) (Boukerche et al., 1989a) .
Electron microscopy ofmenoma-platelet interactions Electron microscopy studies showed that melanoma cells closely interacted with platelets ( Figure 4a ). Melanoma cells at the site of their interaction with platelets formed extrusions or processes which penetrated into the platelet aggregates ( Figure 4b ) (Boukerche et al., 1989a) . Addition to a platelet-tumour cell mixture of anti-TSP MAb LYP8 resuled in a signifant decrease in the size of platelet aggregates (Figure 4c) . Moreover, platelet-melanoma cell intractions could not be observed, confirming the aggregometry results (Figure 4c ). Moreover, in the presence of LYP8, the tumour cell surface did not show cytopLamic extrusion or processes (Figure 4c MAb LYP18 (Figure 5a ). coated wells in the presence of M3Da. cells was not released into the supernatant (less than 1% of the total TSP bound LYP8 was recovered in the supematant). Similarly, an antiMAb, LYP18, had no effect on attachment but inhibited spreading of M3Da. cells on TSP (Figure 6b) (Lawler et al., 1988; Tuszynsi et al., 1989) . This receptor (4A1) has been shown to be expssed by M3Da and plays, as previously indicated, a crucial role in melanoma-platelet interacion and in vivo melanoma tumour growth (Boukerche et al., 1989a,b; Marshal et al., 1991; Felding-Habermann et al., 1992) . Reults in this study and previous work (Lawler et al., 1988; Tuszynski et al., 1989) (1987, 1992) , who showed that whole TSP and a peptide (CSVTCG) (Mustard et al., 1972) .
Under these conditons, TSP relased by M3Da. cells will not bind to platelets that have not undergone release (Leung, 1984; Boukerche and McGregor, 1988) . In view of these results, it appears that ADP-activated platelets need to interact with melanoma cell-surface receptors presumably via amA3 to undergo complete degranulation as observed in electron-micrgrphs obtained in this study and in a previous work (Boukerche et al., 1989a) . Platelet-melanoma interactions may therefore be initiated by: (1) (Leung, 1984, Boukerche and McGregor, 1988 (Majack et al., 1988; Abbadia et al., 1993) . Alternatively, MAb LYP8 binding to TSP may block critical interactions between melanoma cells and stromal matrices that are vital for successful angiogenesis (Tolsma et al., 1993; Dameron et al., 1994) .
TSP is a multidomain glycoprotein that binds to a number of adhesive ptors (Asch et al., 1987; Lawler et al., 1988;  Roberts (Lawler u Tuszynski et al., 1989) suggest that TSP interacts with mA. Inhibition by LYP8 of TSP-mediated M3Da.
spreading and melanoma-platelet interaction could be the result, as previously suggested in this study, of steric or conformational changes of TSP induced by LYP8 (Dixit et al., 1986) . Our data do not exclude the possibility that, in addition to aCm, TSP may bind to other receptors (i.e. heparan sulphate proteoglycans) in view of the lack of effect of LYP8 in inhibiting cell attachment of M3Da. to TSPcoated wells (Roberts, 1988; Asch et al., 1991) .
Our results are consistent with recent studies of Castle et al. (1991) showing the importance of TSP by transfecting human squamous carcinoma cells with the TSP cDNA antisense expression vector and decreasing the tumorigenic phenotype of these cells. Moreover, the CSVTCG TSP peptide and its analogue was shown to block cell adhesion, platelet aggregation and tumour cell metastasis (Tuszynski et al., 1992; Byck and McGregor, 1992 (Nicolson, 1988) . Reagents such as MAbs against TSP and peptides derived from TSP could not only be used as a new therapeutic approach in the control of tumour metastasis of malignant melanoma, but may also contribute to the elucidation on the role of TSP in cancer biology.
